Technical Feasibility of Quantitative Susceptibility Mapping Radiomics for Predicting Deep Brain Stimulation Outcomes in Parkinson Disease

定量磁化率成像放射组学预测帕金森病深部脑刺激疗效的技术可行性

阅读:1

Abstract

BACKGROUND AND OBJECTIVES: Parkinson disease (PD) patients with motor complications are often considered for deep brain stimulation (DBS) surgery. Predicting symptom improvement to separate DBS responders and nonresponders remains an unmet need. Currently, DBS candidacy is evaluated using the levodopa challenge test (LCT) to confirm dopamine responsiveness and diagnosis. However, prediction of DBS success by measuring presurgical symptom improvement associated with levodopa dosage changes is highly problematic. Quantitative susceptibility mapping (QSM) is a recently developed MRI method that depicts brain iron distribution. As the substantia nigra and subthalamic nuclei are well visualized, QSM has been used in presurgical planning of DBS. Spatial features resulting from iron distribution in these nuclei have been previously linked with disease progression and motor symptom severity. Given its clear target depiction and prior findings regarding susceptibility and PD, this study demonstrates the technical feasibility of predicting DBS outcomes from presurgical QSM. METHODS: A novel presurgical QSM radiomics approach using a regression model is presented to predict DBS outcome according to spatial features in QSM deep gray nuclei. To overcome limited and noisy training data, data augmentation using label noise injection or "compensation" was used to improve outcome prediction of the regression model. The QSM radiomics model was evaluated on 67 patients with PD who underwent DBS at 2 medical centers. RESULTS: The QSM radiomics model predicted DBS improvement in the Unified Parkinson Disease Rating Scale at Center 1 and Center 2 with Pearson correlation , ( ) and , ( ), respectively. LCT failed to predict DBS improvement at Center 1 and Center 2 with Pearson correlation ( ) and ( ), respectively. CONCLUSION: QSM radiomics has potential to accurately predict DBS outcome in treating patients with PD, offering a valuable alternative to the time-consuming and low-accuracy LCT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。